rs193922916 — APP A673V (Aβ A2V)

Recessive pathogenic APP missense variant causing early-onset Alzheimer's disease in homozygotes; heterozygous carriers are unaffected due to a dominant-negative inhibition of amyloid aggregation

See your personal result for APP

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

APP A673V — The Recessive Mutation That Is Both Pathogenic and Protective

The amyloid precursor protein (APP) gene encodes a large transmembrane protein whose sequential cleavage by beta-secretase (BACE1)11 beta-secretase (BACE1)
The enzyme that makes the first cut in APP, releasing the C99 fragment that is subsequently cleaved by gamma-secretase to produce amyloid-beta peptides and gamma-secretase generates the amyloid-beta (Aβ) peptides central to Alzheimer's disease pathology. Most pathogenic APP mutations cluster around the cleavage sites and accelerate Aβ production; most operate via autosomal dominant inheritance.

The A673V variant is an exception on both counts. Discovered in 2009 in an Italian family by Di Fede et al.22 Di Fede et al.
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009;323:1473–7, A673V follows strict autosomal recessive inheritance — disease occurs only when both APP copies carry the mutation. Heterozygous relatives who carry a single copy remain cognitively unaffected. This unusual pattern arises because the mutant Aβ peptide interferes with the aggregation of normal wild-type Aβ, creating a dominant-negative protective effect that is lost when no wild-type peptide is present (i.e., in homozygotes).

The Mechanism

Position 673 in the APP protein (position 2 in the Aβ peptide, hence the alternative designation Aβ A2V) sits immediately adjacent to the BACE1 beta-secretase cleavage site. The A673V substitution changes an alanine to a valine at this critical junction, with two consequences that differ dramatically based on gene dosage.

In the homozygous state, Zhang et al. 201733 Zhang et al. 2017
BACE1 Cleavage Site Selection Critical for Amyloidogenesis. J Neurosci 2017;37:6915–25 showed that A673V shifts BACE1 preferential cleavage from the Glu11 site to the Asp1 site, markedly elevating the amyloidogenic C99/C89 ratio and driving excess Aβ production. The mutant A2V-Aβ peptide then forms oligomers with a distinctive polymer-network morphology — connecting hydrophobic residues on external surfaces — that is more aggregation-prone than wild-type, leading to accelerated fibrillization and neurotoxicity.

In the heterozygous state, something remarkable occurs: when A2V-mutant and wild-type Aβ peptides co-exist, Messa et al. 201444 Messa et al. 2014
J Biol Chem 2014;289:24143–52 demonstrated that the mixed assemblies form structures nearly identical to wild-type aggregates, but with slower kinetics (characteristic time τ = 3 hours versus 1.5 hours for pure A2V and 6.7 hours for wild-type). Di Fede et al. showed that co-incubation "conferred instability on Aβ aggregates and inhibited amyloidogenesis and neurotoxicity," explaining why one normal APP allele fully protects carriers despite the presence of the pathogenic A2V peptide.

The neuropathological fingerprint is distinctive. Giaccone et al. 201055 Giaccone et al. 2010
Acta Neuropathol 2010;120:803–12 documented extensive amyloid deposition in homozygous brain tissue with an atypical topographic pattern: cerebellar involvement was pronounced and the striatum was relatively spared — the opposite of the hierarchical spread seen in sporadic Alzheimer's disease. Cerebrovascular amyloid deposition was particularly prominent.

The Evidence

The original Di Fede et al. 2009 Science paper66 Di Fede et al. 2009 Science paper identified A673V in a proband with early-onset Alzheimer-type dementia and her younger sister showing initial cognitive decline — both homozygous. Multiple heterozygous relatives in the same family were examined and found to be cognitively unaffected, establishing the recessive Mendelian pattern.

The variant is vanishingly rare: the A allele was not observed in any of 478 alleles in the ALFA database. It appears primarily in Italian families, with only a handful of homozygous cases documented in the world literature. ClinVar (variation ID 18106) classifies it as pathogenic for Alzheimer disease based on OMIM-curated evidence (SCV000040032.2).

The dominant-negative anti-amyloidogenic effect of the heterozygous state has inspired a therapeutic direction. Cimini et al. 201677 Cimini et al. 2016 developed a cell-permeable fusion peptide (Aβ1-6A2VTAT(D)) that mimics the heterozygous protective state, showing reversal of Aβ1-42-induced synaptopathy in both cell culture and mouse models. This line of research remains in early-stage preclinical development.

Practical Actions

For heterozygous carriers (AG genotype): the recessive mechanism means your single A allele does not elevate your personal Alzheimer's risk above population baseline. The clinical relevance is entirely reproductive — two carrier parents have a 25% chance per pregnancy of producing a homozygous child. Genetic counselling before conceiving and partner testing resolve the actual risk.

For homozygous individuals (AA genotype): this is a severe early-onset Alzheimer's disease genotype. Cognitive and neurological assessment with a specialist in neurodegenerative disease is indicated immediately. Clinical genetic counselling for the individual and family members is essential.

Interactions

The most important clinical interaction at this locus is the contrast with rs63750847 (APP A673T, the Icelandic protective variant). Both variants affect the identical codon — A673T substitutes threonine and is associated with ~50% reduced Alzheimer's risk, while A673V substitutes valine and causes recessive disease. The opposing consequences of two different substitutions at the same nucleotide position illustrate how precisely BACE1 substrate recognition can be tuned by single amino acid changes.

APOE4 (rs429358) modifies risk for sporadic Alzheimer's disease and could theoretically act as a modifier for the rate or severity of amyloid accumulation in the unusual context of a homozygous A673V carrier, though no direct clinical data on this compound situation exists given the extreme rarity of A673V homozygotes.

Genotype Interpretations

What each possible genotype means for this variant.

GG Non-Carrier Normal

No APP A673V mutation — standard amyloid precursor protein function at this site

You carry two copies of the common G allele at rs193922916, meaning your APP protein has the normal alanine at position 673. This is the predominant genotype worldwide; the A673V pathogenic allele is vanishingly rare, documented primarily in a small number of Italian families. You have no elevated risk of APP A673V-related early-onset Alzheimer's disease from this variant.

AA Homozygous Affected High Risk

Homozygous for APP A673V — pathogenic for early-onset recessive Alzheimer's disease

In the homozygous state, both APP alleles produce the A673V-mutant amyloid precursor protein. BACE1 processing shifts from the protective Glu11 cleavage site to the amyloidogenic Asp1 site, elevating C99 production and downstream Aβ generation. The A2V mutant Aβ peptide then forms polymer-network oligomers with unusual hydrophobic surface exposure that aggregate more rapidly than wild-type Aβ and are neurotoxic. Because no wild-type Aβ is present to exert the dominant-negative protective interaction, amyloid accumulation proceeds unchecked.

Brain pathology in documented homozygotes showed extensive amyloid plaques and cerebrovascular amyloid deposition with a distinctive distribution: pronounced cerebellar involvement and relative striatal sparing, contrasting with the hierarchical cortical-to-subcortical progression of sporadic Alzheimer's. Tau pathology was also present. The overall severity was comparable to or greater than typical early-onset familial Alzheimer's disease.

This variant is classified as pathogenic in ClinVar (variation ID 18106) based on OMIM-curated evidence from the Di Fede et al. (2009) Science paper, the definitive description of this allele. The OMIM allelic variant number is 104760.0022.

First-degree relatives should be offered cascade genetic testing: biological parents are obligate carriers; siblings have a 50% probability of being carriers.

AG Heterozygous Carrier Carrier

Carrier of one APP A673V allele — personal Alzheimer's risk not elevated; reproductive implications exist

The A673V variant occupies codon 673 of APP, corresponding to position 2 in the amyloid-beta peptide (A2V). In the heterozygous state, the mutant A2V-Aβ peptide co-exists with normal wild-type Aβ in roughly equal quantities. The two peptides interact in a way that disrupts the mutant's tendency to form pathological oligomeric assemblies — the wild-type Aβ acts as a molecular chaperone that normalises aggregation kinetics and prevents neurotoxicity. This dominant-negative mechanism is the reason heterozygous carriers are protected despite producing an inherently pathogenic peptide.

The implication for reproductive planning: both you and your partner would need to carry the A allele to be at risk of having an affected (AA) child. Given the extreme rarity of this allele, a partner of non-Italian descent is very unlikely to carry it, but targeted testing removes uncertainty if you are planning a family.